Property | Value |
overview
|
Our research focuses primarily on developing molecularly targeted radiotracers for noninvasive imaging of various diseases and disease-related biomarkers using positron emission tomography (PET) and for targeted radiopharmaceutical therapy of cancers. For this, we employ a variety of molecular scaffolds, including small molecules, peptides, and antibodies, and radiolabel them with appropriate radionuclides, such as fluorine-18, radioiodines, or zirconium-89 for imaging. Once successfully validated, the resulting imaging agents can have wide-ranging applications in the diagnosis and treatment of specific diseases and aid in new drug development. The work involves a multidisciplinary approach and collaborations with several other experts, including chemists, biologists, physicists, and physicians, to successfully advance the most promising radiopharmaceutical products for human use.
|